L1CAM expression in endometrial carcinomas: An ENITEC collaboration study

Louis J.M. Van Der Putten, Nicole C.M. Visser, Koen Van De Vijver, Maria Santacana, Peter Bronsert, Johan Bulten, Marc Hirschfeld, Eva Colas, Antonio Gil-Moreno, Angel Garcia, Gemma Mancebo, Fransesc Alameda, Jone Trovik, Reidun K. Kopperud, Jutta Huvila, Stefanie Schrauwen, Martin Koskas, Francine Walker, Vit Weinberger, Lubos MinarEva Jandakova, Marc P.L.M. Snijders, Saskia Van Den Berg-Van Erp, Xavier Matias-Guiu, Helga B. Salvesen, Frederic Amant, Leon F.A.G. Massuger, Johanna M.A. Pijnenborg

Research output: Contribution to journalArticleResearchpeer-review

70 Citations (Scopus)


© 2016 Cancer Research UK. Background: Identification of aggressive endometrioid endometrial carcinomas (EECs) and non-endometrioid carcinomas (NEECs) is essential to improve outcome. L1 cell adhesion molecule (L1CAM) expression is a strong prognostic marker in stage I EECs, but less is known about L1CAM expression in advanced-stage EECs and NEECs. This study analyses L1CAM expression in a clinically representative cohort of endometrial carcinomas. Methods: The expression of L1CAM was immunohistochemically determined in 1199 endometrial carcinomas, treated at one of the European Network for Individualized Treatment of Endometrial Cancer (ENITEC) centres. Staining was considered positive when >10% of the tumour cells expressed L1CAM. The association between L1CAM expression and several clincopathological characteristics and disease outcome was calculated. Results: In all, L1CAM was expressed in 10% of the 935 stage I EECs, 18% of the 160 advanced stage EECs, and 75% of the 104 NEECs. The expression of L1CAM was associated with advanced stage, nodal involvement, high tumour grade, non-endometrioid histology, lymphovascular space invasion, and distant recurrences in all cases, and with reduced survival in the EECs, but not in the NEECs. Conclusions: The expression of L1CAM is a strong predictor of poor outcome in EECs, but not NEECs. It is strongly associated with non-endometrioid histology and distant spread, and could improve the postoperative selection of high-risk endometrial carcinomas. The value of L1CAM expression in the preoperative selection of high-risk endometrial carcinomas should be studied.
Original languageEnglish
Pages (from-to)716-724
JournalBritish Journal of Cancer
Issue number6
Publication statusPublished - 6 Sept 2016


  • L1CAM
  • endometrial cancer
  • endometrioid
  • immunohistochemistry
  • non-endometrioid


Dive into the research topics of 'L1CAM expression in endometrial carcinomas: An ENITEC collaboration study'. Together they form a unique fingerprint.

Cite this